NEJM Knowledge+ Welcomes Dr. Alex Djuricich as NEJM Group Education Editor - NEJM Knowledge+
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer | NEJM
Alex Stern | NEJM Dive (2023) | Available for Sale | Artsy
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer | NEJM
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Oxygen in the Treatment of Coronary Occlusion in the Home | NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer | NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Alex Stern, NEJM Flower, 2022 | Trotter&Sholer
The Role of PIEZO2 in Human Mechanosensation | NEJM
NEJM paper retracted for “inaccuracies in the analytic database and data analyses” – Retraction Watch
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation | NEJM
Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma | NEJM
Alex Evans - Senior Software Engineer - VIDA | LinkedIn
Early versus Later Anticoagulation for Stroke with Atrial Fibrillation | NEJM
Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction | NEJM
NEJM Knowledge+ Welcomes Dr. Alex Djuricich as NEJM Group Education Editor - NEJM Knowledge+
إبراهيم الحربي Ibrahim Alharbi on X: "Perioperative Management of Anticoagulant and Antiplatelet Therapy. Source : NEJM May 2023 https://t.co/5wdDGYjnms https://t.co/ywiJfrBomg" / X
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM
Alex Stern | NEJM Every Word (2023) | Available for Sale | Artsy
